Literature DB >> 27038853

Inadequate critical appraisal of studies in systematic reviews of time to diagnosis.

Elise Launay1, Jérémie F Cohen2, Michèle Morfouace2, Christèle Gras-Le Guen3, Philippe Ravaud4, Martin Chalumeau2.   

Abstract

OBJECTIVE: To analyze tools used to critically appraise primary studies included in systematic reviews (SRs) of time to diagnosis (TTD). STUDY DESIGN AND
SETTING: We systematically searched MEDLINE via PubMed and Web of Science for SRs of TTD published up to the end of February 2015; we identified and characterized tools used for critical appraisal and classified their items.
RESULTS: From 1,936 articles identified, we included 45 SRs that aimed to summarize the available information on the length (n = 16), determinants (n = 31), and/or consequences (n = 14) of TTD. For the 23 SRs (51%) reporting a critical appraisal process, 21 different tools were used, with 232 items assessing quality of reporting (64%), risk of bias or threats to generalizability (43%), statistical issues (5%), and/or an unclear domain (0.5%); 11% were specific to TTD issues. Overall, 36% of the 45 SRs assessed risk of bias and/or threats to generalizability.
CONCLUSION: Assessment of risk of bias and threats to generalizability in primary studies included in SRs of TTD is infrequent, nonstandardized and rarely concerns TTD study specificities. These findings highlight the need for guidance on critical appraisal of studies of TTD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Critical appraisal; Early diagnosis; Methodological quality; Risk of bias; Systematic review; Time to diagnosis

Mesh:

Year:  2016        PMID: 27038853     DOI: 10.1016/j.jclinepi.2016.03.013

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST).

Authors:  Elise Launay; Jérémie F Cohen; Patrick M Bossuyt; Pierre Buekens; Jonathan Deeks; Timothy Dye; Richard Feltbower; Andrea Ferrari; Michael Kramer; Mariska Leeflang; David Moher; Karel G Moons; Erik von Elm; Philippe Ravaud; Martin Chalumeau
Journal:  BMC Med       Date:  2016-09-27       Impact factor: 8.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.